Cart
sales@molnova.com
Home - Products - Others - Other Targets - Lumiliximab

Lumiliximab

CAS No. 357613-86-6

Lumiliximab( —— )

Catalog No. M36903 CAS No. 357613-86-6

Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 591 In Stock
10MG 938 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Lumiliximab
  • Note
    Research use only, not for human use.
  • Brief Description
    Lumiliximab (IDEC-152) is a primate-ized chimeric antibody targeting CD23 rhesus monkey/human chimeric antibody with inhibitory effects on IgE antibody production for the study of allergic diseases.
  • Description
    Lumiliximab (Anti-CD23 Recombinant Antibody) is an anti-CD23 monoclonal antibody that inhibits allergen-induced responses.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    357613-86-6
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Poole JA, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products
Sign In Join Free